CommercialPrior AuthMedium impact
Reyvow™ (lasmiditan) (Revised)
Humana·Neurology, General Practice·Commercial
Effective date
Mar 27, 2024
We identified it
Jun 25, 2026
Summary
Humana updated its Reyvow™ (lasmiditan) prior authorization policy on March 27, 2024. The policy requires prior authorization for acute migraine treatment and mandates documented previous treatment failure or contraindication to Nurtec or Ubrelvy before approval. Key safety restrictions include limiting use to no more than 4 migraines per 30-day period and requiring 8-hour driving/machinery restrictions post-dose.
Action Required
By March 27, 2024 (or immediately if claims are being processed): (1) Billing team must update billing system to require prior authorization for all Reyvow (lasmiditan) pharmacy claims on Humana Commercial plans. (2) Update claim submission workflow to mandate documentation of patient's previous treatment, intolerance, or contraindication to either Nurtec or Ubrelvy before authorization can be requested. (3) Add requirement to prior auth request forms to capture and verify the 4-migraine-per-30-day safety threshold. (4) Notify prescribing providers that Reyvow requires prior auth through your standard communication channels and update internal documentation templates. (5) Train front-desk and billing staff that this is a pharmacy benefit requiring prior authorization, not a medical claim. Claims submitted without prior authorization or missing the required Nurtec/Ubrelvy history will be denied.